Stocks On the Move: ChannelAdvisor Corp, Genworth Financial Inc, and Salix Pharmaceuticals, Ltd.

ECOM, GNW, and SLXP are moving sharply in Friday's trading

Nov 7, 2014 at 11:32 AM
facebook X logo linkedin


Around midday, three of the top market movers are software-as-a-service firm ChannelAdvisor Corp (NYSE:ECOM), wealth management issue Genworth Financial Inc (NYSE:GNW), and drugmaker Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). Here's a quick roundup of how ECOM, GNW, and SLXP are performing on the charts so far.

  • ECOM is soaring this morning, following a slimmer-than-expected third-quarter loss and a 26% jump in revenue. At last check, the shares are 42.3% higher at $17.36, despite receiving price-target cuts to $21 at Raymond James and $19 at BMO -- though the firms reiterated their respective "outperform" and "market perform" evaluations. Longer term, ChannelAdvisor Corp shares have struggled considerably, down roughly 58% year-to-date. As such, short sellers have been active, as 23.7% of the stock's float is sold short. At ECOM's average daily trading level, it would take approximately two weeks to buy back all of these bearish bets. In fact, some of today's gains may be attributable to short sellers covering their positions.

  • GNW continues to plummet in the wake of its huge quarterly loss, reported yesterday. For the second straight session, the shares are down double digits, off 10.6% at $7.74, and fresh off another annual low of $7.17. While shareholders can't be too happy about these developments, it appears plenty of option players should be. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Genworth Financial Inc has racked up a 50-day put/call volume ratio of 0.49 -- just 16 percentage points from an annual high.

  • Finally, SLXP has tumbled 37.2% to trade at $87.09, following a third-quarter earnings miss, a reduced full-year forecast, and an audit probe amid the sudden resignation of the company's chief financial officer. What's more, the stock has been hit with price-target reductions at no fewer than six brokerage firms, and downgrades from a trio of analysts. If Salix Pharmaceuticals, Ltd. keeps falling, it risks getting hit with additional bearish attention. After all, 12 out of 14 covering analysts sport "strong buy" ratings on the shares (versus two "holds" and not a single "sell"), and the stock's consensus 12-month price target stands at a lofty $168.59.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI